1. Introduction {#sec1}
===============

MicroRNAs (miRNAs) are evolutionarily conserved, endogenous small noncoding, and single-stranded RNAs of 18--22 nucleotides in length. They often negatively regulate gene targets by translational inhibition or mRNA degradation \[[@B1], [@B2]\]. It has been revealed that the posttranscriptional regulation could influence various biological processes including apoptosis, differentiation, proliferation, stress response, and metabolism \[[@B3], [@B4]\]. miRNAs could also be able to predict cancer prognosis due to their crucial roles in cancer progression and metastasis. Previous studies have explored that deregulated miRNAs with aberrant expression levels were closely correlated with cancer prognosis and even could be a novel kind of biomarkers for various cancer types \[[@B5], [@B6]\].

Interestingly, the miR-200 family is a typical and most extensively studied example in functional miRNAs. The miR-200 family, composed of five miRNA sequences (miR-141, miR-200a, miR-200b, miR-200c, and miR-429) and located in two clusters in the genome, is involved in the epithelial to mesenchymal transition (EMT) through regulation of E-cadherin expression via suppression of ZEB1 and ZEB2 \[[@B7], [@B8]\]. Recent studies have reported that miR-200 cluster is overexpressed in different tumors and played a critical role in mRNA degradation or inhibition through targeted binding to the relevant 3′-untranslated region (UTR) \[[@B9]\]. miR-200 family has been shown to offer a great potential in both cancer diagnosis and prognosis. Despite the potential roles of miR-200 family high expression in prognosis for cancer patients that have been attempted, no definite conclusions have been drawn so far. Meta-analysis can explore the authentic and comprehensive results through incorporating all available evidences to get a relatively precise and accurate estimation by using statistical analyses \[[@B10]\]. Thus, we have performed the current meta-analysis to explore the potential associations between miR-200 family and cancer prognosis, which efforts should hold great promise in verifying the potential of miRNAs as biomarkers for evaluating therapeutic efficacy and prognosis of various cancers.

2. Methods {#sec2}
==========

2.1. Ethics Statement {#sec2.1}
---------------------

The PRISMA statement was used to conduct the current meta-analysis \[[@B11]\]. No patient\'s privacy or clinical samples were involved in this study; hence, the ethical approval was not required.

2.2. Search Strategy {#sec2.2}
--------------------

Literature resources including PubMed, Cochrane Library, Embase, CBM, and CNK were introduced to search eligible studies, by using the terms "microRNA OR miRNA OR miR-200 OR miR-141 OR miR-429 OR miR-200 family OR miR-200 cluster," "survival OR prognosis OR prognostic," and "cancer OR tumor OR tumour OR neoplasm OR neoplasma OR neoplasia OR carcinoma OR cancers OR tumors OR tumours OR neoplasms OR neoplasmas OR neoplasias OR carcinomas." Last search of current investigation was updated on November 25th, 2017. Additionally, the publication language was only limited to English and Chinese. In case of omission, we identified the reference lists of the relevant articles and reviewed articles to seek for the potentially relevant studies. Conventionally, we have not contacted the corresponding authors even if the relevant data were unavailable.

2.3. Inclusion and Exclusion Criteria {#sec2.3}
-------------------------------------

Studies complied with the following criteria could be identified: (1) clinical study about the association of miR-200 family with cancer prognosis and (2) relevant data of the hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) to evaluate its associations were available. Studies which met the following four criteria were excluded: (1) the available data regarding associations was absent; (2) similar or duplicate study (when the same or similar cohort was applied, after careful examination, the most complete information was included); (3) other types of articles such as reviews or abstracts; and (4) studies involved with cell lines or animal models.

2.4. Data Extraction {#sec2.4}
--------------------

In the light of inclusion and exclusion criteria, we extracted the relevant data from each eligible study. If disagreements were noticed, we are clearly open to discussion by each other (Wen Liu and Kaiping Zhang) or reviewed by a third author (Pengfei Wei). The data on first author, publication year, study country, age, cancer type, miRNA category, sample source, sample size, follow-up time, test method, survival outcome, analysis method, HR (95% CI), and the cut-off value were extracted. We have not contacted any author of the original researches even if the essential information could not be available. Besides, patient sources came from Asia, Europe, and North America. Sample sources were stratified into tissue, blood, formalin-fixed and paraffin-embedded (FFPE), and tissue microarray (TMA). Test methods included TaqMan, in situ hybridization (ISH), and reverse transcription polymerase chain reaction (RT-PCR). Sample sizes were separated into ≥100 and \<100. Cancer types included epithelial ovarian cancer (EOC), breast cancer (BC), nonsmall cell lung cancer (NSCLC), gastric cancer (GC), and colorectal cancer (CRC). Analyses methods were divided into univariate analysis and multivariate analysis. Patients\' prognostic outcomes included overall survival (OS), relapse-free survival (RFS), progression-free survival (PFS), and disease-free survival (DFS).

3. Statistical Analysis {#sec3}
=======================

We have explored the association of miR-200 family with cancer prognosis by applying Review Manager software (RevMan 5, The Cochrane Collaboration, Oxford, UK) and Stata software (Version 12.0, Stata Corporation, College Station, TX). HR and 95% CI were collected for assessing the prognostic value of high expression of miR-200 family in various cancers. Meanwhile, the heterogeneity has been assessed via chi-square-based *Q* and *I*^2^ test across studies (no heterogeneity *I*^2^ \< 25%, moderate heterogeneity *I*^2^ = 25%--50%, extreme heterogeneity *I*^2^ \> 50%) \[[@B12]\]. In case of extreme heterogeneity (*I*^2^ \> 50% or *P* \< 0.01 for *Q* test), we used random-effects (DerSimonian and Laird method) model \[[@B13]\]. Otherwise, fixed-effects (Mantel-Haenszel method) model was introduced \[[@B14]\]. One-way sensitivity analyses which individually removed publications in meta-analysis were conducted to assess results\' stability. It mainly explores the impact of specific study upon mixed HR. In Begg\'s funnel plots, logHR was plotted against SE. *P* value less than 0.05 indicated that there was a bias of the study \[[@B15]\]. Additionally, different subgroups consisted of patient source, cancer type, test method, sample source, sample size, and miR-200 component were conducted.

4. Results {#sec4}
==========

4.1. Characteristics of the Studies {#sec4.1}
-----------------------------------

Consequently, 23 studies consisted of 3038 samples satisfied the eligible criteria \[[@B16]--[@B38]\] ([Figure 1](#fig1){ref-type="fig"}).

The principal characteristics of the eligible studies were summarized in [Table 1](#tab1){ref-type="table"}.

Among these studies, Cheng\'s study was involved with three different cohorts of Tianjin cohort, TexGen cohort, and all cohort \[[@B36]\]. Zhu et al. designed a study to detect tissue and serum miRNA expression \[[@B28]\]. Tejero et al. analyzed the role of members of the miR-200 family from NSCLC patients after surgery both in the entire cohort and adenocarcinoma cohort \[[@B30]\]. Maierthaler et al. explore miRNA expression in two different cohorts of nonmetastatic and metastatic CRC \[[@B18]\]. Toiyama et al. conducted a study to detect the prognostic value of the miR-200 family in CRC from blood and FFPE samples. As mentioned above, we treated them independently into meta-analysis \[[@B31]\]. Eventually, this meta-analysis was established based on 29 studies ([Table 2](#tab2){ref-type="table"}). Among these 29 studies, 28 were written in English while one was published in Chinese. The sample sizes ranged from 44 to 527. The cancer types contained ten EOC, one BC, seven NSCLC, two GC, and nine CRC. Meanwhile, one ISH, 24 RT-PCR, and four TaqMan in test methods were applied. According to the sample sources, there were seven FFPE, ten tissue, ten blood, and two TMA. For the survival outcomes, 29 eligible studies were divided into 42 datasets: 29 for OS, six for PFS, five for RFS, and two for DFS. However, the cut-off value for the miR-200 family was inconsistent among these included studies ([Table 2](#tab2){ref-type="table"}).

4.2. Meta-Analysis of OS {#sec4.2}
------------------------

In univariate analysis, 19 studies were involved in current meta-analysis to assess the prognosis of miR-200 family overexpression in various cancers. High expression of miR-200 family was found to be associated with unfavorable OS (HR = 1.32, 95% CI: 1.14--1.54, *P* \< 0.001) ([Figure 2(a)](#fig2){ref-type="fig"}). Besides, it indicated that there were certain associations via subanalyses regarding patient source, cancer type, test method, sample source, sample size, and miR-200 component ([Table 3](#tab3){ref-type="table"}).

In multivariate analysis, 24 studies were included in meta-analysis to explore the prognostic value of the miR-200 family. As a result, high expression of the miR-200 family in various cancers was associated with unfavorable overall survival (HR = 1.32, 95% CI: 1.16--1.49, *P* \< 0.001) ([Figure 2(b)](#fig2){ref-type="fig"}). Likewise, a similar result was found in different subgroups ([Table 3](#tab3){ref-type="table"}).

4.3. Meta-Analysis of RFS/PFS/DFS {#sec4.3}
---------------------------------

In univariate analysis, there were three studies, four studies, and one study involved with RFS, PFS, and DFS, respectively. Correspondingly, five studies, five studies, and two studies were collected in multivariate analysis, respectively. Ultimately, we found that no association of high expression of the miR-200 family was detected with RFS (univariate: HR = 1.02, 95% CI: 0.96--1.09, *P* = 0.47; multivariate: HR = 1.07, 95% CI: 1.00--1.14, *P* = 0.07) ([Figure 3](#fig3){ref-type="fig"}), PFS (univariate: HR = 0.96, 95% CI: 0.54--1.70, *P* = 0.88; multivariate: HR = 1.17, 95% CI: 0.86--1.61, *P* = 0.32) ([Figure 4](#fig4){ref-type="fig"}), and DFS (univariate: HR = 0.90, 95% CI: 0.74--1.09, *P* = 0.29; multivariate: HR = 0.98, 95% CI: 0.68--1.41, *P* = 0.90) ([Figure 5](#fig5){ref-type="fig"}).

4.4. Sensitivity Analysis {#sec4.4}
-------------------------

Each single included study was deleted at a time to assess the specific effect of the individual data on the pooled HRs, and one-way sensitivity analysis suggested that most pooled results were relatively stable. Among them, the pooled results of OS, RFS, and PFS in both univariate analysis and multivariate analysis were shown in Figures [6(a)](#fig6){ref-type="fig"}, [6(b)](#fig6){ref-type="fig"}, Figures [7(a)](#fig7){ref-type="fig"}, [7(b)](#fig7){ref-type="fig"}, and Figures [8(a)](#fig8){ref-type="fig"}, [8(b)](#fig8){ref-type="fig"}, respectively. As shown in [Figure 6(b)](#fig6){ref-type="fig"}, after excluding the study conducted by Antolín et al. \[[@B22]\], heterogeneity was slightly reduced between miR-200 family overexpression and OS under multivariate analysis (*I*^2^ from 75.1% to 73.3%), while the pooled results remained unchanged (multivariate: HR = 1.40, 95% CI: 1.21--1.63, *P* \< 0.001). Likewise, as shown in [Figure 8(a)](#fig8){ref-type="fig"}, the similar result was found between miR-200 family overexpression and PFS under univariate analysis (*I*^2^ from 85.1% to 80.4%), and the pooled results remained unchanged (univariate: HR = 0.85, 95% CI: 0.38--1.88, *P* = 0.684) after excluding the aforementioned study \[[@B22]\].

4.5. Publication Bias Evaluation {#sec4.5}
--------------------------------

Begg\'s funnel plot indicated that there was a significant publication bias in meta-analysis of OS under both univariate analysis (*P* = 0.028) and multivariate analysis (*P* \< 0.001). However, no publication bias was found in meta-analysis of RFS (univariate: *P* = 0.760; multivariate: *P* = 0.855), PFS (univariate: *P* = 1.000; multivariate: *P* = 0.087), and DFS (univariate: *P* = 0.296; multivariate: *P* = 0.308).

5. Discussion {#sec5}
=============

Generally, cancer progression and blood-borne metastasis are the primary factors contributed to the great majority of cancer deaths. The specific biomarkers of metastatic phenotype hold great promise in individualized therapy and improved prognosis prediction in several neoplastic diseases \[[@B39]\]. In recent decades, to explore the clinically useful cancer signatures remains to be research hotpot due to the complexity of cancer. Gene expression signatures of carcinomas have led to new classifications of cancer subgroups and also carried prognostic and predictive information \[[@B40]\]. miRNAs are small noncoding RNAs that regulate human protein-coding gene expression of specific mRNAs by either translational repression or degradation. miRNA expression signatures have distinct functions in controlling the cell cycle, proliferation, invasion, and metastasis \[[@B41]\], which could thus be developed into a potential prognostic signature \[[@B42]\]. The latest miRBase release contains 24,521 miRNA loci from 206 species, further processed to produce 30,424 mature miRNA products \[[@B43]\]. To date, significant miRNA expression changes have been observed in multiple cancers analyzed by profiling and next generation sequencing technologies \[[@B44]\].

The miR-200 family of miRNAs consists of five members grouped into two independent transcriptional clusters: miR-200a, miR-200b, and miR-429 on chromosome 1 (1p36.33), and miR-141 and miR-200c on chromosome 12 (12p13.31). Deregulation of the miR-200 family of microRNAs has been involved in cell plasticity, apoptosis, molecular subtype, oestrogen regulation, control of the growth and function of stem cells, and regulation of the downstream transcriptional program that mediate distant metastasis \[[@B45]\]. Cancer progression is associated with a dynamic process of epithelial-to-mesenchymal transition (EMT), during which epithelial cells lose their cell polarity and cell-cell adhesion and gain migratory as well as invasive properties by downregulating E-cadherin and upregulating vimentin expression \[[@B46], [@B47]\]. The miR-200 family members may play a major role in the suppression of EMT and metastasis \[[@B48]\]. Deregulation of miR-200 in cancer cell lines caused upregulation of E-cadherin and reduced motility of cancer cells. Conversely, inhibition of miR-200 reduced E-cadherin expression, increased expression of vimentin, and induced EMT \[[@B49]\]. In addition, the miR-200 family is known as a key transcriptional regulator of EMT and the maintenance of a less invasive and aggressive epithelial phenotype by targeting ZEB1 and ZEB2, two important transcriptional repressors of the E-cadherin gene \[[@B48]\]. ZEB was inhibited by miR-200 members at the posttranscriptional level by binding to highly conserved target sites in their 3′-UTR; the functional link of ZEB factors with the miR-200 family in a double negative feedback loop is known as the ZEB/miR-200 feedback loop \[[@B50]\]. It also has been reported that several tumor suppressor genes, including BRD7, BAP1, GATA, CLOCK, and PTPN12, might be potential targets of the miR-200 family \[[@B51], [@B52]\].

To date, studies focused on the association of high expression of the miR-200 family with cancer prognosis have yielded conflicting results. Notably, small sample-sized studies lacking statistical power often have resulted in apparently contradicting conclusions. Meta-analysis is a useful tool for providing convincing evidence as it could present inconsistent results from different studies to get a relatively precise result. As far as we know, the current meta-analysis is the first try to comprehensively assess the correlation of miR-200 cluster high expression with cancer prognosis. We have explored the potential associations in overall population and the corresponding subgroups. Consequently, of particular interest is the finding of significant correlation between high expression of miR-200 cluster and poor OS by two different statistical methods. Likewise, a similar result was found in different subgroups. However, no association of miR-200 family was detected with RFS/PFS/DFS.

In the current meta-analysis, significant heterogeneity was found, which required careful interpretation and searched for influencing factors by further subgroup analyses. Consequently, impact of ethnicity, detection methods, cancer types, sample size, and sample source on prognosis in patients was considerable, which should be taken into consideration when evaluating the prognosis of cancer for patients. Some potential or undiscovered factors including adjustment for surgery, radiation, chemotherapy, socioeconomic status, and tumor characteristics should not be ignored. Moreover, there was a significant publication bias in meta-analysis of OS under both univariate analysis and multivariate analysis, suggesting that only published studies in English and Chinese might not provide so sufficient evidences. As for RFS/PFS/DFS, we did not perform subgroup analyses due to relatively fewer eligible studies. Although the studies regarding various tumors without a consistent cut-off value may influence the ultimate results and the heterogeneity suggested that potential or undiscovered factors might be ignored, a certain relationship of high expression of the miR-200 family in cancer prognosis was found in the current study.

6. Conclusion {#sec6}
=============

In summary, the current study is the first original meta-analysis to address the correlation between miR-200 family expression and prognosis for cancer patients. A significant correlation was explored in overall population as well as the corresponding subgroups. Concretely, it presented that miR-200 family overexpression might be associated with poor OS to some extent, while no association was detected between high miR-200 family expression and RFS/PFS/DFS. In the future, detailed investigations comprising large cohort size from multicenter are required to confirm our conclusions.
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![Forest plot of the association between high expression of the miR-200 family in various tumors and OS under different types of analysis. (a) Univariate analysis; (b) multivariate analysis. The squares and horizontal lines correspond to the study-specific HR and 95% CI. The area of the squares reflects the weight. The diamond represents the summary HR and 95% CI. CI = confidence interval, HR = hazard ratio.](DM2018-6071826.002){#fig2}

![Forest plot of the association between high expression of the miR-200 family in various tumors and RFS under different types of analysis. (a) Univariate analysis; (b) multivariate analysis. The squares and horizontal lines correspond to the study-specific HR and 95% CI. The area of the squares reflects the weight. The diamond represents the summary HR and 95% CI. CI = confidence interval, HR = hazard ratio.](DM2018-6071826.003){#fig3}

![Forest plot of the association between high expression of the miR-200 family in various tumors and PFS under different types of analysis. (a) Univariate analysis; (b) multivariate analysis. The squares and horizontal lines correspond to the study-specific HR and 95% CI. The area of the squares reflects the weight. The diamond represents the summary HR and 95% CI. CI = confidence interval, HR = hazard ratio.](DM2018-6071826.004){#fig4}

![Forest plot of the association between high expression of the miR-200 family in various tumors and DFS under different types of analysis. (a) Univariate analysis; (b) multivariate analysis. The squares and horizontal lines correspond to the study-specific HR and 95% CI. The area of the squares reflects the weight. The diamond represents the summary HR and 95% CI. CI = confidence interval, HR = hazard ratio.](DM2018-6071826.005){#fig5}

![One-way sensitivity analysis of high expression of the miR-200 family in various tumors with OS under different types of analysis. (a) Univariate analysis; (b) multivariate analysis. Individually removed the studies and suggested that the results of this meta-analysis were relatively stable.](DM2018-6071826.006){#fig6}

![One-way sensitivity analysis of high expression of the miR-200 family in various tumors with RFS under different types of analysis. (a) Univariate analysis; (b) multivariate analysis. Individually removed the studies and suggested that the results of this meta-analysis were stable.](DM2018-6071826.007){#fig7}

![One-way sensitivity analysis of high expression of the miR-200 family in various tumors with PFS under different types of analysis. (a) Univariate analysis; (b) multivariate analysis. Individually removed the studies and suggested that the results of this meta-analysis were relatively stable.](DM2018-6071826.008){#fig8}

###### 

Main characteristics of the eligible studies.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author                Year   Country   Age             Cancer type   MicroRNA                                         Sample size   Follow-up, median (range)   Outcome
  --------------------------- ------ --------- --------------- ------------- ------------------------------------------------ ------------- --------------------------- ------------
  Zou J. \[[@B16]\]           2017   China     NA              EOC           miR-429                                          72            NA                          OS/PFS

  Han Y. \[[@B17]\]           2017   China     NA              CRC           miR-429                                          71            34.2                        OS

  Maierthaler M. \[[@B18]\]   2017   Germany   70 (33--92)\    CRC           miR-200a, miR-200b, miR-200c, miR-141, miR-429   527           NA                          OS/RFS
                                               68.0 (36--92)                                                                                                            

  Si L. \[[@B19]\]            2017   China     60.5 (41--78)   NSCLC         miR-200c                                         110           NA                          OS/DFS

  Meng X. \[[@B20]\]          2016   Germany   60 (23--91)     EOC           miR-200a, miR-200b, miR-200c                     163           20 (1--136)                 OS/RFS

  Dong S. J. \[[@B21]\]       2016   China     56 (31--79)     CRC           miR-429                                          116           NA                          OS

  Antolín S. \[[@B22]\]       2015   Spain     54.8 (29--73)   BC            miR-200c, miR-141                                57            74.6 (74.2--77.7)           OS/PFS

  Gao Y. C. \[[@B23]\]        2015   China     NA              EOC           miR-200c, miR-141                                93            NA                          OS

  Lu Y. B. \[[@B24]\]         2015   China     NA              GC            miR-141                                          95            NA                          OS

  Liu J. Y. \[[@B25]\]        2015   China     57.48           EOC           miR-200a                                         44            26 (5--49)                  OS/PFS

  Cao Q. \[[@B26]\]           2014   China     58 (26--88)     EOC           miR-200a, miR-200b, miR-200c                     100           36.8 (6--56)                OS

  Kim M. K. \[[@B27]\]        2014   Korea     64 (26--77)     NSCLC         miR-200c                                         72            31 (1--135)                 OS

  Zhu W. \[[@B28]\]           2014   China     59              NSCLC         miR-429                                          70            NA                          OS

  Song F. \[[@B29]\]          2014   China     60.5            GC            miR-200a, miR-200b, miR-200c                     385           35 (1--112)                 OS/PFS

  Tejero R. \[[@B30]\]        2014   Spain     65 (35--85)     NSCLC         miR-200c/141                                     155           43 (2--160)                 OS

  Toiyama Y. \[[@B31]\]       2014   Japan     67              CRC           miR-200c                                         182           NA                          OS

  Sun Q. \[[@B32]\]           2014   China     NA              EOC           miR-200a                                         53            56.79 (11--98)              OS

  Liu X. G. \[[@B33]\]        2012   China     NA              NSCLC         miR-200c, miR-141                                70            24                          OS

  Chao A. \[[@B34]\]          2012   China     NA              EOC           miR-200a                                         176           40 (3--109)                 OS/RFS

  Marchini S. \[[@B35]\]      2011   Italy     52 (21--82)     EOC           miR-200b, miR-200c                               144           110.4 (82.8--139.2)         OS/PFS

  Cheng H. \[[@B36]\]         2011   USA       NA              CRC           miR-141                                          156           NA                          OS

  Leskelä S. \[[@B37]\]       2010   Spain     57 (35--85)     EOC           miR-200a, miR-200b, miR-200c, miR-141, miR-429   72            NA                          OS/PFS/RFS

  Hu X. \[[@B38]\]            2009   USA       58.3            EOC           miR-200a                                         55            NA                          OS/PFS
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA: not available; EOC: epithelial ovarian cancer; BC: breast cancer; NSCLC: nonsmall cell lung cancer; GC: gastric cancer; CRC: colorectal cancer; OS: overall survival; DFS: disease-free survival; PFS: progression-free survival; RFS: recurrence- or relapse-free survival; HR: hazard ratio; CI: confidence interval.

###### 

MicroRNA evaluation and survival data of the selected studies.

  First author       Year   Country   Test method   Cancer type   MicroRNA       Sample source   Outcome   HR (95% CI)                                             Cut-off value
  ------------------ ------ --------- ------------- ------------- -------------- --------------- --------- ------------------------------------------------------- ----------------------------------
  Zou J.             2017   China     RT-PCR        EOC           miR-429        Tissue          OS        \(U\) 0.641 (0.412--0.996)/(M) 0.763 (0.458--1.270)     \>0.532
  Zou J.             2017   China     RT-PCR        EOC           miR-429        Tissue          PFS       \(U\) 0.661 (0.478--0.915)/(M) 0.710 (0.504--1.001)     
                                                                                                                                                                   
  Han Y.             2017   China     RT-PCR        CRC           miR-429        Tissue          OS        \(M\) 1.852 (1.019--3.326)                              Median
                                                                                                                                                                   
  Maierthaler M.-1   2017   Germany   TaqMan        CRC           miR-200a       Blood           OS        \(U\) 0.929 (0.707--1.211)/(M) 1.053 (0.791--1.401)     Median
  Maierthaler M.-1   2017   Germany   TaqMan        CRC           miR-200b       Blood           OS        \(U\) 0.704 (0.524--0.945)/(M) 0.772 (0.570--1.045)     
  Maierthaler M.-1   2017   Germany   TaqMan        CRC           miR-200c       Blood           OS        \(U\) 0.808 (0.646--1.010)/(M) 0.840 (0.659--1.070)     
  Maierthaler M.-1   2017   Germany   TaqMan        CRC           miR-141        Blood           OS        \(U\) 0.925 (0.713--1.200)/(M) 1.038 (0.785--1.374)     
  Maierthaler M.-1   2017   Germany   TaqMan        CRC           miR-429        Blood           OS        \(U\) 0.951 (0.734--1.235)/(M) 0.968 (0.721--1.300)     
  Maierthaler M.-2   2017   Germany   TaqMan        CRC           miR-200a       Blood           OS        \(U\) 1.198 (0.986--1.456)/(M) 1.227 (1.008--1.495)     
  Maierthaler M.-2   2017   Germany   TaqMan        CRC           miR-200b       Blood           OS        \(U\) 1.172 (0.946--1.453)/(M) 1.208 (0.975--1.497)     
  Maierthaler M.-2   2017   Germany   TaqMan        CRC           miR-200c       Blood           OS        \(U\) 1.117 (0.947--1.318)/(M) 1.152 (0.975--1.362)     
  Maierthaler M.-2   2017   Germany   TaqMan        CRC           miR-141        Blood           OS        \(U\) 1.071 (0.877--1.305)/(M) 1.105 (0.904--1.350)     
  Maierthaler M.-2   2017   Germany   TaqMan        CRC           miR-429        Blood           OS        \(U\) 1.010 (0.853--1.196)/(M) 1.006 (0.845--1.198)     
  Maierthaler M.-1   2017   Germany   TaqMan        CRC           miR-200a       Blood           RFS       \(U\) 0.929 (0.718--1.203)/(M) 1.031 (0.786--1.353)     
  Maierthaler M.-1   2017   Germany   TaqMan        CRC           miR-200b       Blood           RFS       \(U\) 0.714 (0.539--0.947)/(M) 0.750 (0.561--1.005)     
  Maierthaler M.-1   2017   Germany   TaqMan        CRC           miR-200c       Blood           RFS       \(U\) 0.819 (0.657--1.019)/(M) 0.835 (0.658--1.060)     
  Maierthaler M.-1   2017   Germany   TaqMan        CRC           miR-141        Blood           RFS       \(U\) 0.910 (0.705--1.175)/(M) 0.999 (0.760--1.312)     
  Maierthaler M.-1   2017   Germany   TaqMan        CRC           miR-429        Blood           RFS       \(U\) 0.954 (0.743--1.227)/(M) 1.076 (0.716--1.618)     
  Maierthaler M.-2   2017   Germany   TaqMan        CRC           miR-200a       Blood           RFS       \(U\) 1.175 (0.973--1.420)/(M) 1.200 (0.989--1.456)     
  Maierthaler M.-2   2017   Germany   TaqMan        CRC           miR-200b       Blood           RFS       \(U\) 1.109 (0.893--1.377)/(M) 1.143 (0.919--1.422)     
  Maierthaler M.-2   2017   Germany   TaqMan        CRC           miR-200c       Blood           RFS       \(U\) 1.076 (0.911--1.272)/(M) 1.100 (0.930--1.302)     
  Maierthaler M.-2   2017   Germany   TaqMan        CRC           miR-141        Blood           RFS       \(U\) 1.057 (0.871--1.284)/(M) 1.085 (0.890--1.321)     
  Maierthaler M.-2   2017   Germany   TaqMan        CRC           miR-429        Blood           RFS       \(U\) 1.080 (0.916--1.272)/(M) 1.078 (0.910--1.277)     
                                                                                                                                                                   
  Si L.              2017   China     RT-PCR        NSCLC         miR-200c       Tissue          OS        \(M\) 2.095 (1.241--3.536)                              The 2−ΔΔCq
  Si L.              2017   China     RT-PCR        NSCLC         miR-200c       Tissue          DFS       \(M\) 1.647 (1.049--2.585)                              
                                                                                                                                                                   
  Meng X.            2016   Germany   RT-PCR        EOC           miR-200a       Blood           OS        \(U\) 1.7 (0.8--3.5)                                    Median
  Meng X.            2016   Germany   RT-PCR        EOC           miR-200b       Blood           OS        \(U\) 2.7 (1.3--5.7)/(M) 2.8 (1.1--6.8)                 
  Meng X.            2016   Germany   RT-PCR        EOC           miR-200c       Blood           OS        \(U\) 2.4 (1.2--4.9)/(M) 2.5 (1.1--6.1)                 
  Meng X.            2016   Germany   RT-PCR        EOC           miR-200a       Blood           RFS       \(U\) 1.1 (0.6--1.9)                                    
  Meng X.            2016   Germany   RT-PCR        EOC           miR-200b       Blood           RFS       \(U\) 1.6 (0.9--2.8)                                    
  Meng X             2016   Germany   RT-PCR        EOC           miR-200c       Blood           RFS       \(U\) 2.0 (1.1--3.6)/(M) 1.7 (0.8--3.6)                 
                                                                                                                                                                   
  Dong S. J.         2016   China     RT-PCR        CRC           miR-429        Tissue          OS        \(M\) 2.296 (1.105--4.528)                              Median
                                                                                                                                                                   
  Antolín S.         2015   Spain     RT-PCR        BC            miR-200c       Blood           OS        \(U\) 1.38 (1.11--1.71)/(M) 2.79 (1.01--7.7)            \>1.29 relative expression value
  Antolín S.         2015   Spain     RT-PCR        BC            miR-200c       Blood           PFS       \(U\) 1.37 (1.09--1.71)/(M) 3.33 (1.22--9.07)           
  Antolín S.         2015   Spain     RT-PCR        BC            miR-141        Blood           OS        \(M\) 0.986 (0.942--1.032)                              
  Antolín S.         2015   Spain     RT-PCR        BC            miR-141        Blood           PFS       \(M\) 0.987 (0.95--1.025)                               
                                                                                                                                                                   
  Gao Y. C.          2015   China     RT-PCR        EOC           miR-200c       Blood           OS        \(U\) 3.14 (1.67--5.93)                                 −ΔCt method with 95% CI
  Gao Y. C.          2015   China     RT-PCR        EOC           miR-141        Blood           OS        \(U\) 1.83 (1.00--3.33)                                 
                                                                                                                                                                   
  Lu Y. B.           2015   China     RT-PCR        GC            miR-141        Tissue          OS        \(M\) 2.972 (1.297--10.001)                             Median
                                                                                                                                                                   
  Liu J. Y.          2015   China     RT-PCR        EOC           miR-200a       Tissue          OS        \(M\) 0.354 (0.149--0.840)                              Log 2−ΔΔCt
  Liu J. Y.          2015   China     RT-PCR        EOC           miR-200a       Tissue          PFS       \(M\) 0.395 (0.210--0.742)                              
                                                                                                                                                                   
  Cao Q              2014   China     ISH           EOC           miR-200a       Tissue          OS        \(U\) 22.69 (1.32--50.53)/(M) 17.26 (1.36--36.98)       Median
  Cao Q.             2014   China     ISH           EOC           miR-200b       Tissue          OS        \(U\) 20.28 (1.20--42.28)/(M)15.41 (1.13--31.36)        
  Cao Q.             2014   China     ISH           EOC           miR-200c       Tissue          OS        \(U\) 21.42 (1.26--48.33)/(M) 16.22 (1.27--33.81)       
                                                                                                                                                                   
  Kim M. K.          2014   Korea     RT-PCR        NSCLC         miR-200c       FFPE            OS        \(M\) 3.67 (1.17--11.45)                                Median
                                                                                                                                                                   
  Zhu W.-1           2014   China     RT-PCR        NSCLC         miR-429        Tissue          OS        \(U\) 1.686 (0.570--4.984)/(M) 2.749 (0.706--10.707)    Mean
  Zhu W.-2           2014   China     RT-PCR        NSCLC         miR-429        Blood           OS        \(U\) 6.458 (1.409--29.593)/(M) 12.875 (2.295--72.23)   
                                                                                                                                                                   
  Song F.            2014   China     RT-PCR        GC            miR-200a       TMA             OS        \(U\) 0.82 (0.57--1.20)/(M) 0.72 (0.47--1.13)           Median
  Song F.            2014   China     RT-PCR        GC            miR-200b       TMA             OS        \(U\) 0.87 (0.60--1.26)/(M)0.93 (0.63--1.41)            
  Song F.            2014   China     RT-PCR        GC            miR-200c       TMA             OS        \(U\) 1.19 (0.80--1.77)/(M) 1.32 (0.82--2.12)           
  Song F.            2014   China     RT-PCR        GC            miR-200a       TMA             DFS       \(U\) 0.81 (0.58--1.14)/(M) 0.67 (0.45--0.99)           
  Song F.            2014   China     RT-PCR        GC            miR-200b       TMA             DFS       \(U\) 0.84 (0.60--1.18)/(M) 0.82 (0.56--1.19)           
  Song F.            2014   China     RT-PCR        GC            miR-200c       TMA             DFS       \(U\) 1.08 (0.76--1.54)/(M) 1.06 (0.70--1.60)           
                                                                                                                                                                   
  Tejero R.-1        2014   Spain     TaqMan        NSCLC         miR-200c/141   FFPE            OS        \(M\) 2.787 (1.087--7.148)                              Mean
  Tejero R.-2        2014   Spain     TaqMan        NSCLC         miR-200c/141   FFPE            OS        \(M\) 10.649 (2.433--46.608)                            
                                                                                                                                                                   
  Toiyama Y.-1       2014   Japan     RT-PCR        CRC           miR-200c       Blood           OS        \(U\) 2.43 (1.26--4.68)/(M)2.67 (1.28--5.67)            Median
  Toiyama Y.-2       2014   Japan     RT-PCR        CRC           miR-200c       FFPE            OS        \(U\) 0.56 (0.28--1.10)                                 
                                                                                                                                                                   
  Sun Q.             2014   China     RT-PCR        EOC           miR-200a       TMA             OS        \(U\) 0.58 (0.08--4.05)                                 Median (≥12.623)
                                                                                                                                                                   
  Liu X. G.          2012   China     RT-PCR        NSCLC         miR-200c       Tissue          OS        \(U\) 6.020 (1.344--26.971)                             2−ΔΔCt \> 2.0
  Liu X. G.          2012   China     RT-PCR        NSCLC         miR-141        Tissue          OS        \(U\) 4.135 (0.467--36.597)                             
  Chao A.            2012   China     RT-PCR        EOC           miR-200a       FFPE            OS        \(M\) 1.466 (0.786--2.734)                              Log ratio \> 1.3
  Chao A.            2012   China     RT-PCR        EOC           miR-200a       FFPE            RFS       \(M\) 1.213 (0.70--2.101)                               
                                                                                                                                                                   
  Marchini S.        2011   Italy     RT-PCR        EOC           miR-200b       Tissue          OS        \(U\) 2.137 (0.801--5.701)/(M) 2.051 (0.640--6.570)     \>25%
  Marchini S.        2011   Italy     RT-PCR        EOC           miR-200b       Tissue          PFS       \(U\) 3.197 (1.417--7.213)/(M) 2.335 (0.857--6.363)     
  Marchini S.        2011   Italy     RT-PCR        EOC           miR-200c       Tissue          OS        \(U\) 0.309 (0.112--0.850)/(M) 0.244 (0.076--0.785)     
  Marchini S.        2011   Italy     RT-PCR        EOC           miR-200c       Tissue          PFS       \(U\) 0.392 (0.174--0.885)/(M) 0.419 (0.146--1.204)     
                                                                                                                                                                   
  Cheng H.-1         2011   USA       RT-PCR        CRC           miR-141        Blood           OS        \(U\) 3.80 (1.46--9.91)/(M) 1.36 (0.45--4.14)           2−ΔΔCt
  Cheng H.-2         2011   USA       RT-PCR        CRC           miR-141        Blood           OS        \(U\) 4.83 (2.06--11.35)/(M) 3.41 (1.36--8.56)          
  Cheng H.-3         2011   USA       RT-PCR        CRC           miR-141        Blood           OS        \(U\) 3.61 (1.96--6.65)/(M) 2.40 (1.18--4.86)           
                                                                                                                                                                   
  Leskelä S.         2010   Spain     RT-PCR        EOC           miR-200a       FFPE            PFS       \(M\) 1.22 (0.57--2.58)                                 75% of positive cells
  Leskelä S.         2010   Spain     RT-PCR        EOC           miR-200b       FFPE            PFS       \(M\) 1.35 (0.62--2.93)                                 
  Leskelä S.         2010   Spain     RT-PCR        EOC           miR-200c       FFPE            PFS       \(M\) 2.24 (1.00--5.03)                                 
  Leskelä S.         2010   Spain     RT-PCR        EOC           miR-141        FFPE            PFS       \(M\) 2.35 (0.98--5.59)                                 
  Leskelä S.         2010   Spain     RT-PCR        EOC           miR-429        FFPE            PFS       \(M\) 2.10 (0.92--4.79)                                 
  Leskelä S.         2010   Spain     RT-PCR        EOC           miR-429        FFPE            RFS       \(M\) 2.01 (1.11--3.66)                                 
  Leskelä S.         2010   Spain     RT-PCR        EOC           miR-429        FFPE            OS        \(M\) 2.08 (1.03--4.20)                                 
                                                                                                                                                                   
  Hu X.              2009   USA       RT-PCR        EOC           miR-200a       FFPE            OS        \(U\) 0.70 (0.03--14.29)                                \>11
  Hu X.              2009   USA       RT-PCR        EOC           miR-200a       FFPE            PFS       \(U\) 0.64 (0.22--1.81)                                 

EOC: epithelial ovarian cancer; BC: breast cancer; NSCLC: nonsmall cell lung cancer; NMIBC: nonmuscle-invasive bladder cancer; GC: gastric cancer; CRC: colorectal cancer; OS: overall survival; DFS: disease-free survival; PFS: progression-free survival; RFS: recurrence- or relapse-free survival; HR: hazard ratio; CI: confidence interval; U: univariate analysis; M: multivariate analysis; ISH: in situ hybridization; RT-PCR: reverse transcription-polymerase chain reaction; FFPE: formalin-fixed and paraffin-embedded; TMA: tissue microarray; OS: overall survival; DFS: disease-free survival; PFS, progression-free survival; RFS: recurrence- or relapse-free survival.

###### 

Stratified analysis of the high expression of the miR-200 family and overall survival.

  Categories          Subgroups   Univariate analyses       Multivariate analyses                                                                                                       
  ------------------- ----------- ------------------------- ----------------------- --------- --------- --------- ------------------------- ----------------------- --------- --------- ---------
  All                             19                        **1.32 (1.14--1.54)**   \<0.001   77.50%    \<0.001   24                        **1.32 (1.16--1.49)**   \<0.001   75.10%    \<0.001
                                                                                                                                                                                        
  Patient source      Asia        10                        **1.91 (1.26--2.92)**   0.003     80.10%    \<0.001   13                        **1.98 (1.34--2.90)**   0.001     78.20%    \<0.001
  Europe              5           1.07 (0.95--1.21)         0.286                   66.80%    \<0.001   8         1.11 (0.99--1.24)         0.071                   67.10%    \<0.001   
  North America       4           **3.81 (2.46--5.90)**     \<0.001                 0.00%     0.685     3         **2.37 (1.44--3.91)**     0.001                   0.00%     0.457     
                                                                                                                                                                                        
  Cancer type         EOC         7                         **2.18 (1.23--3.86)**   0.008     79.90%    \<0.001   7                         **1.98 (1.03--3.80)**   0.039     81.80%    \<0.001
  CRC                 7           1.12 (0.96--1.31)         0.140                   77.70%    \<0.001   8         **1.15 (1.02--1.30)**     0.026                   60.10%    0.001     
  NSCLC               3           **3.36 (1.64--6.89)**     0.001                   0.00%     0.411     6         **2.91 (1.99--4.26)**     \<0.001                 33.40%    0.185     
  GC                  1           0.94 (0.75--1.17)         0.565                   1.90%     0.361     2         1.10 (0.72--1.68)         0.669                   62.30%    0.047     
  BC                  1           **1.38 (1.11--1.71)**     0.003                   /         /         1         1.46 (0.54--3.91)         0.454                   75.10%    0.045     
                                                                                                                                                                                        
  Test method         RT-PCR      16                        1.64 (1.24--2.16)       0.001     75.30%    \<0.001   19                        **1.57 (1.23--1.99)**   \<0.001   75.10%    \<0.001
  ISH                 1           **21.42 (7.54--60.83)**   \<0.001                 0.00%     0.996     1         **16.28 (6.28--42.24)**   \<0.001                 0.00%     0.995     
  TaqMan              2           1.01 (0.95--1.08)         0.686                   47.70%    0.046     4         1.07 (0.95--1.20)         0.249                   58.80%    0.005     
                                                                                                                                                                                        
  Sample source       FFPE        2                         0.57 (0.29--1.10)       0.095     0.00%     0.890     5                         **2.27 (1.56--3.32)**   \<0.001   43.10%    0.135
  Tissue              5           **3.19 (1.19--8.52)**     0.021                   84.40%    \<0.001   9         **2.04 (1.13--3.68)**     0.017                   80.70%    \<0.001   
  Blood               10          **1.34 (1.15--1.57)**     \<0.001                 79.00%    \<0.001   9         **1.14 (1.02--1.28)**     0.019                   68.30%    \<0.001   
  TMA                 2           0.93 (0.75--1.16)         0.527                   0.00%     0.519     1         0.94 (0.73--1.21)         0.649                   40.90%    0.184     
                                                                                                                                                                                        
  Sample size         ≧100        11                        **1.25 (1.06--1.47)**   0.007     78.90%    \<0.001   14                        **1.29 (1.11--1.49)**   0.001     71.60%    \<0.001
  \<100               8           **1.74 (1.10--2.75)**     0.018                   68.50%    0.001     10        **1.84 (1.17--2.90)**     0.008                   79.60%    \<0.001   
                                                                                                                                                                                        
  miR-200 component   miR-200a    7                         1.14 (0.81--1.61)       0.438     64.80%    0.009     6                         1.07 (0.72--1.59)       0.723     78.30%    \<0.001
  miR-200b            6           1.38 (0.88--2.16)         0.166                   82.10%    \<0.001   6         1.36 (0.89--2.08)         0.158                   76.70%    0.001     
  miR-200c            11          **1.38 (1.01--1.89)**     0.040                   82.40%    \<0.001   10        **1.62 (1.12--2.33)**     0.010                   79.30%    \<0.001   
  miR-141             7           **2.01 (1.26--3.21)**     0.003                   83.50%    \<0.001   7         1.24 (0.99--1.56)         0.060                   68.00%    0.005     
  miR-429             5           0.99 (0.73--1.34)         0.953                   62.20%    0.032     8         **1.41 (1.01--1.98)**     0.043                   70.30%    0.001     

EOC: epithelial ovarian cancer; BC: breast cancer; NSCLC: nonsmall cell lung cancer; GC: gastric cancer; CRC: colorectal cancer; RT-PCR: reverse transcription-polymerase chain reaction; ISH: in situ hybridization; FFPE: formalin-fixed and paraffin-embedded; TMA: tissue microarray; HR: hazard ratio; CI: confidence interval; Ph: *P* value of the heterogeneity test.
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